TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Process: Preferred Process: (II) obtained in step (i) is further purified with a mixture of water and an organic solvent including alcohol e.g. methanol, ethanol, propanol, butanol, pentanol, ketone e.g. acetone methyl ethyl ketone, methyl isobutyl ketone and/or diethyl ketone. In step (c), more than 80% of the total amount of the methanol used is recovered. The clear solution obtained in step (f) is optionally, extracted with a water immiscible organic solvent including esters e.g. ethyl acetate, halogenated solvents e.g. dichloromethane, chloroform, ethers e.g. diethyl ether or hydrocarbons e.g. hexane, or toluene. Preferred Components: The amount of phosphorylcholine chloride calcium salt used with respect to cytidine 5'-monophosphate is 1.5-3 moles equivalent, preferably 2-2.5 moles equivalent. The calcium precipitating agent is oxalic acid (preferred), sodium phosphate, sodium hydrogen phosphate, potassium phosphate and/or potassium hydrogen phosphate. The amount of calcium precipitating agent used with respect to phosphorylcholine chloride calcium salt is 0.8-1.2 moles equivalent. In step (g), the solution is subjected to nanofilteration for removal of low molecular weight compounds and for concentrating the solution. ACTIVITY - Neuroprotective; Nootropic; Cerebroprotective; Vulnerary; Vasotropic; Antiparkinsonian; Ophthalmological.    MECHANISM OF ACTION - None given.    EXAMPLE - 74.12g of Morpholine was added to 100g of cytidine 5'-monophosphate in 1500 ml of methanol. The mixture was heated to 40-45 degrees C and 114.9 g of dicyclohexycarbodiimide was added. The mixture was heated to 50- 55 degrees C for 3-6 hours. Methanolic solution of phophorylcholine chloride (200g of phosphorylcholine calcium salt tetrahydrate and 88ml of concentrated hydrochloric acid dissolved in 1500 ml of methanol) was added to the mixture at 50-55 degrees C and the reaction mixture was stirred at same temperature for 3-6 hours. After completion of reaction, the methanol was recovered under vacuum to obtain thick semisolid mass. The thick semisolid mass was dissolved /suspended in water and the insolubles formed were removed by filtration. 76.47g of Oxalic acid dihydrate was added to the filtrate at 25-30 degrees C, and the mixture was stirred for 1 hour. The precipitated calcium oxalate was filtered off and the pH of filtrate was adjusted to 2-5 using aqueous sodium hydroxide. The clear solution was extracted with dichloromethane. The aqueous solution was subjected to nanofilteration to obtain retentate. The retentate was charcoalized and filtered to obtain a solution comprising cytidine 5'-diphosphocholine (CDP)-choline. The solution comprising CDP-choline was concentrated under vacuum. The CDP-choline in the concentrated solution was converted into its monosodium salt using aqueous sodium hydroxide to form solution-A. The monosodium salt of CDP-choline in the solution-A was precipitated using 2400ml of ethanol. The obtained crude monosodium salt of CDP-choline was treated with methanol, filtered and dried to obtain 75 g of monosodium salt of CDP-choline. The monosodium salt of CDP-choline was further purified by dissolving in water and once again precipitated with ethanol. The precipitate obtained was filtered and dried to obtain 72g of monosodium salt of CDP-choline.